Concept Life Sciences has formed a strategic alliance with OpenBench to enhance drug discovery services for early-stage biotech firms through a fee-for-success model.
This collaboration integrates OpenBench's AI-driven discovery platform with Concept Life Sciences' expertise in medicinal chemistry and in-vitro screening. The partnership aims to expedite the process from target identification to validated hit series, potentially achieving this in just six months while alleviating upfront costs and associated scientific risks for biotech companies.
OpenBench utilizes advanced virtual screening techniques to evaluate trillions of compounds, selecting high-quality candidates for rapid testing by Concept Life Sciences. This innovative approach funds initial discovery activities, charging clients only upon successful validation of hits, thus shifting the financial burden away from them. Concept Life Sciences enhances this model with its comprehensive capabilities, facilitating a streamlined transition toward clinical development across various therapeutic areas.
The partnership addresses the pressing need for cost-effective and efficient drug discovery solutions, especially given the current constraints in biotech funding. By minimizing financial risks and accelerating the development pipeline, this collaboration empowers biotech companies to focus on advancing promising therapeutic candidates.